Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Cost of Revenue: 2010-2024

Historic Cost of Revenue for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $6.5 million.

  • China Pharma Holdings' Cost of Revenue fell 49.63% to $815,871 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 39.65%. This contributed to the annual value of $6.5 million for FY2024, which is 10.67% down from last year.
  • As of FY2024, China Pharma Holdings' Cost of Revenue stood at $6.5 million, which was down 10.67% from $7.3 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Cost of Revenue registered a high of $9.3 million during FY2021, and its lowest value of $6.5 million during FY2024.
  • For the 3-year period, China Pharma Holdings' Cost of Revenue averaged around $7.5 million, with its median value being $7.3 million (2023).
  • Its Cost of Revenue has fluctuated over the past 5 years, first rose by 4.25% in 2021, then decreased by 15.19% in 2023.
  • China Pharma Holdings' Cost of Revenue (Yearly) stood at $8.9 million in 2020, then climbed by 4.25% to $9.3 million in 2021, then fell by 7.48% to $8.6 million in 2022, then declined by 15.19% to $7.3 million in 2023, then declined by 10.67% to $6.5 million in 2024.